Compare Byrna Technologies Inc (BYRN) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Byrna Technologies Inc vs Smith & Nephew plc — how do they compare? Byrna Technologies Inc trades at $4.24 (market cap $106.74M), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 117.5× Byrna Technologies Inc's market cap, and Smith & Nephew plc pays a 2.65% dividend while Byrna Technologies Inc pays none. Which is the better fit depends on your goals.
| BYRN | SNN | |
|---|---|---|
Market Cap | $106.74M | $12.54B |
Sector | Technology | Health |
52-Week High | $27.63 | $38.70 |
52-Week Low | $3.18 | $28.73 |
Enterprise Value | $98.35M | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYRN trades at $4.32, down 10.93% amid weak Q2 2026 results, with revenue declining 42.5% and a significant EPS miss. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with negative net income and ROE. Recent management changes and marketing initiatives aim to address sales challenges, while an ongoing legal investigation adds uncertainty.
The outlook is mixed; analyst consensus is 71% buy with potential from new leadership and product expansion, but execution risk is high given profit declines and competitive pressures. Investors should weigh turnaround efforts against persistent operational weaknesses and legal overhangs for near-term volatility.
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
